Abstract:Background: LCL161, a novel Smac mimetic, is known to have anti-tumor activity and improve chemosensitivity in various cancers. However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small cell lung cancer (NSCLC) remain unknown. Methods: Cellular inhibitor of apoptotic protein 1 and 2 (cIAP1&2) expression in NSCLC tissues and adjacent non-tumor tissues were assessed by immunohistochemistry. The correlations between cIAP1&2 expression and clinicopathological characteristics, prognosis were analyzed. Cell viability and apoptosis were measured by MTT assays and Flow cytometry. Western blot and co-immunoprecipitation assay were performed to measure the protein expression and interaction in NF-kB pathway. siRNA-mediated gene silencing and caspases activity assays were applied to demonstrate the role and mechanisms of cIAP1&2 and RIP1 in lung cancer cell apoptosis. Mouse xenograft NSCLC models were used in vivo to determine the therapeutic efficacy of LCL161 alone or in combination with paclitaxel. Results: The expression of cIAP1 and cIAP2 in Non-small cell lung cancer (NSCLC) tumors was significantly higher than that in adjacent normal tissues. cIAP1 was highly expressed in patients with late TNM stage NSCLC and a poor prognosis. Positivity for both cIAP1 and cIAP2 was an independent prognostic factor that indicated a poorer prognosis in NSCLC patients. LCL161, an IAP inhibitor, cooperated with paclitaxel to reduce cell viability and induce apoptosis in NSCLC cells. Molecular studies revealed that paclitaxel increased TNFα expression, thereby leading to the recruitment of various factors and the formation of the TRADD-TRAF2-RIP1-cIAP complex. LCL161 degraded cIAP1&2 and released RIP1 from the complex. Subsequently, RIP1 was stabilized and bound to caspase-8 and FADD, thereby forming the caspase-8/RIP1/FADD complex, which activated caspase-8, caspase-3 and ultimately lead to apoptosis. In nude mouse xenograft experiments, the combination of LCL161 and paclitaxel degraded cIAP1,2, activated caspase-3 and inhibited tumor growth with few toxic effects. Conclusion: Thus, LCL161 could be a useful agent for the treatment of NSCLC in combination with paclitaxel.

Dasatinib Promotes Paclitaxel-Induced Necroptosis in Lung Adenocarcinoma with Phosphorylated Caspase-8 by C-Src

Lnccrla Enhanced Chemoresistance in Lung Adenocarcinoma That Underwentepithelial-mesenchymal Transition

lncCRLA Enhanced&nbsp;Chemoresistance in Lung Adenocarcinoma That Underwentepithelial-mesenchymal Transition

C-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma

Fibronectin Protects Lung Cancer Cells Against Docetaxel-Induced Apoptosis by Promoting Src and Caspase-8 Phosphorylation

P2.03a-059 LCL161 Increases Paclitaxel-Induced Apoptosis by Degrading Ciap1 and Ciap2 in NSCLC: Topic: Clinical Trials

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation

MLN4924 Neddylation Inhibitor Promotes Cell Death in Paclitaxel-Resistant Human Lung Adenocarcinoma Cells.

Paclitaxel And Ceramide Synergistically Induce Cell Death With Transient Activation Of Egfr And Erk Pathway In Pancreatic Cancer Cells

Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells

Receptor Interactive Protein Kinase 3 Promotes Cisplatin-triggered Necrosis in Apoptosis-Resistant Esophageal Squamous Cell Carcinoma Cells.

Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models

High-mobility Group Box 1 Protein-Mediated Necroptosis Contributes to Dasatinib-Induced Cardiotoxicity.

Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death

Cardenolide glycosides sensitize gefitinib-induced apoptosis in non-small cell lung cancer: inhibition of Na+/K+-ATPase serving as a switch-on mechanism

Cell death in cancer chemotherapy using taxanes

Paclitaxel Impedes EGFR-mutated PC9 Cell Growth via Reactive Oxygen Species-mediated DNA Damage and EGFR/PI3K/AKT/mTOR Signaling Pathway Suppression

The Anticancer Efficacy of Paclitaxel Liposomes Modified with Mitochondrial Targeting Conjugate in Resistant Lung Cancer

The role of Caspase-1/GSDMD-mediated pyroptosis in Taxol-induced cell death and a Taxol-resistant phenotype in nasopharyngeal carcinoma regulated by autophagy

The Novel Triazolonaphthalimide Derivative Lss-11 Synergizes The Anti-Proliferative Effect Of Paclitaxel Via Stat3-Dependent Mdr1 And Mrp1 Downregulation In Chemoresistant Lung Cancer Cells